Recent studies suggest that glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide (marketed as Ozempic and Wegovy), may reduce the risk of dementia and Alzheimer’s disease through multiple neuroprotective mechanisms -> https://www.drugs.com/medical-answers/glp-1-drugs-ozempic-reduce-dementia-risk-3579245/ #diabetes #dementia #glp1